Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
作者: Rana R. McKayGustavo E. RodriguezXun LinMarina D. KaymakcalanOle-Petter R. HamnvikVenkata S. SabbisettiRupal S. BhattRonit SimantovToni K. Choueiri
作者单位: 11Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
22Pfizer Oncology, Pfizer Inc., New York, New York.
33Division of Endocrinology, Diabetes, and Hypertension, Brigham and Woman's Hospital, Boston, Massachusetts.
44Department of Pharmacy and Clinical Support, Dana-Farber Cancer Institute, Boston, Massachusetts.
55Department of Nephrology, Brigham and Woman's Hospital, Boston, Massachusetts.
66Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
刊名: Clinical Cancer Research, 2015, Vol.21 (11), pp.2471-2479
来源数据库: Duke University Press
DOI: 10.1158/1078-0432.CCR-14-2332
原始语种摘要: Purpose: The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.Experimental Design: We conducted a pooled analysis of mRCC patients treated on phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan–Meier method.Results: A total of 4,736 patients were included, of whom 1,487 received ASIs and 783 received other antihypertensive agents. Overall, ASI users demonstrated improved overall survival (OS) compared with users of other antihypertensive agents (adjusted HR, 0.838, P = 0.0105, 26.68 vs. 18.07 months) and...
全文获取路径: Duke University Press  (合作)

  • demonstrated 探明的储量
  • targeted 对准目标的
  • observed 观察到的
  • several 各自
  • evaluate 求...的值
  • investigate 
  • ASI Automated System Initialization
  • users 使用者
  • angiotensin 血管紧张肽
  • viability 生活力